Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00891306
Recruitment Status : Completed
First Posted : May 1, 2009
Last Update Posted : September 29, 2011
The Clinical Trial Company
Information provided by (Responsible Party):
Amsterdam Molecular Therapeutics

April 30, 2009
May 1, 2009
September 29, 2011
February 2009
August 2010   (Final data collection date for primary outcome measure)
Reduction of triglyceride (TG) concentrations [ Time Frame: 12 weeks ]
Same as current
Complete list of historical versions of study NCT00891306 on Archive Site
  • Reduction of chylomicrons and/or chylomicron-TG ratio [ Time Frame: 12 weeks ]
  • To determine the biological activity and expression of the lipoprotein lipase [LPLS447X] transgene product [ Time Frame: 14 weeks ]
  • To assess the safety profile [ Time Frame: 14 weeks ]
  • To assess shedding of viral vector [ Time Frame: 14 weeks ]
Same as current
Not Provided
Not Provided
Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects
An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects
This trial is designed to expand the currently available data on the safety and efficacy of alipogene tiparvovec treatment in lipoprotein lipase deficiency (LPLD) and to further the understanding of possible mechanisms of action of the therapy.

LPLD is a rare autosomal recessive disorder, characterized by the presence of marked chylomicronemia and hence hypertriglyceridemia. Clinically the most severe manifestation of chylomicronemia, is acute pancreatitis, which can be lethal. There is no effective therapy available to modulate the course of the illness and prevent complications for these patients. The current clinical management consists of severe reduction of dietary fat that is hard if not almost impossible to comply with. LPLD subjects continue to experience pancreatitis attacks, and are admitted to intensive care units on several occasions.

Alipogene tiparvovec corrects or restores lipoprotein lipase (LPL) function long term, and hence reverses some symptoms, halts the disease progression and prevents further complications. Alipogene tiparvovec gene therapy ensures that a catabolically beneficial variant of the human LPL gene, LPL[S447X] is expressed and active in the relevant tissues in humans. Delivery of the gene is realized via intramuscular injection of an adeno-associated viral vector, pseudotyped with AAV1 capsids.

Phase 2
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Familial Lipoprotein Lipase Deficiency
  • Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
    intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
    Other Names:
    • Glybera
    • AMT-011
  • Drug: mycophenolate mofetil
    oral, 2 g/day, day -3 till week 12
    Other Name: CellCept
  • Drug: cyclosporine
    oral, 3 mg/kg/day, day -3 till week 12
    Other Name: Neoral
  • Drug: methylprednisolone
    single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
    Other Name: Solumedrol®
Experimental: Treatment arm
Gene Therapy
  • Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
  • Drug: mycophenolate mofetil
  • Drug: cyclosporine
  • Drug: methylprednisolone

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2011
August 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Being diagnosed with LPLD defined as:

    • Confirmed homozygosity or compound heterozygosity for the mutations in the LPL gene, resulting in LPL deficiency
    • Having a post heparin plasma LPL activity of ≤ 20% of normal or a well defined mutation for which it is documented that the LPL mass and activity are within the limits described above
    • Having a history of pancreatitis
    • Having fluctuating TG concentrations with median fasting plasma TG concentrations > 10.00 mmol/L
  • Being in good general physical health with, in the opinion of the investigator:

    • No other clinically significant and relevant abnormalities in the medical history which could interfere with the participation to the study
    • No clinically significant abnormalities at the physical examination which could interfere with the participation to the study
    • No clinically significant abnormalities at the routine laboratory evaluation performed prior to the trial
  • Women of non-child bearing potential or with a negative pregnancy test.
  • Non breast feeding women
  • Women using appropriate contraceptive (if relevant) and their partner using barrier contraception 2 weeks before starting immunosuppressive therapy
  • Men practicing barrier birth control and their partner using appropriate contraception.
  • Willing to fully comply with all study procedures and requirements of the trial such as restrictions to a low-fat diet.

Exclusion Criteria:

  • Having a chronic inflammatory muscle disease.
  • Any current or relevant previous history of serious, severe or unstable physical or psychiatric illness, any medical disorder that may make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures based on the investigator's opinion(eg. malignant neoplasia)
  • Active infectious disease of any nature, including clinically active viral infections
  • Having one of the following outcomes from the blood screening tests after appropriate correction due to the presence of chylomicronemia:

    • Platelet count < 100 x 109 /L
    • Hemoglobin < 6.2 mmol/L
    • Liver function disturbances (bilirubin ≥1.5 x normal, ALT > 2 x ULN (upper limit of normal)
    • CPK > 2 x ULN
    • Cockcroft-Gault estimated creatinine clearance < 50cc/min
    • PT and PTT outside normal range or not determinable unless judged as acceptable for the subjects by the investigator
    • Having a positive test for HIV, Hepatitis B, Hepatitis C or being positive for tuberculosis
  • Obesity defined as body mass index (BMI) > 30 kg/m2
  • Having a recent history of alcohol or drug abuse e.g. barbiturates, cannabinoids and amphetamines, and the subject is positive in a urine screen for drugs of abuse
  • Using anti-coagulants
  • Participation in another clinical trial or receipt of any other investigational drug within 30 days of screening or planning to participate in another clinical trial during the course of the study, except observational studies
  • Subjects which cannot be treated with immunosuppressive medication or steroids
  • Known to be allergic to any constituent of the therapy (including the immune suppressors) or a having a condition that prohibits the use of therapy
  • Received previous treatment with AMT-010, Alipogene tiparvovec or other gene therapy investigational product
  • Requiring a post heparin plasma LPL activity test for diagnostic confirmation and having a history of heparin induced thrombocytopenia or other heparin related complications
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Amsterdam Molecular Therapeutics
Amsterdam Molecular Therapeutics
The Clinical Trial Company
Principal Investigator: Daniel Gaudet, MD, Ph.D. ECOGENE-21 Clinical Trial Center / Centre de santé et de services sociaux de Chicoutimi, Chicoutimi Hospital, Quebec, Canada
Amsterdam Molecular Therapeutics
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP